Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer
The purpose of this study is to determine whether UTD1 Injection in combination with capecitabine is effective in the treatment of advanced metastatic breast cancer using capecitabine as a control.
Breast Cancer
DRUG: UTD1 Injection plus capecitabine|DRUG: Capecitabine
Progresssion free survival (PFS), 2.0 years
Overall survival (OS), 4 years|Objective Response Rate(ORRï¼‰, 1.5 years
The purpose of this study is to determine whether UTD1 Injection in combination with capecitabine is effective in the treatment of advanced metastatic breast cancer using capecitabine as a control.